迪哲(江苏)医药股份有限公司

Dizal Pharmaceutical Co., Ltd (Ticker: 688192) is a commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for the treatment of cancer and immunological diseases. Leveraging its deep expertise in translational science and molecular design, the company has built a globally competitive pipeline of five clinical-stage assets, with two leading assets in global pivotal studies and one already approved.